WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018020358) CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/020358 International Application No.: PCT/IB2017/054314
Publication Date: 01.02.2018 International Filing Date: 17.07.2017
IPC:
C07K 7/56 (2006.01) ,A61K 38/12 (2006.01) ,A61P 37/00 (2006.01) ,A61P 13/12 (2006.01)
Applicants: PFIZER INC.[US/US]; 235 East 42nd Street New York, New York 10017, US
Inventors: CHE, Ye; US
FENG, Yiqing; US
HAYWARD, Matthew Merrill; US
HEPWORTH, David; US
JONES, Peter; US
KAILA, Neelu; US
PAPAIOANNOU, Nikolaos; US
Agent: WALDRON, Roy F.; US
Priority Data:
62/368,26229.07.2016US
62/517,21509.06.2017US
Title (EN) CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS
(FR) PEPTIDES CYCLIQUES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR C5
Abstract: front page image
(EN) The invention relates to cyclic peptide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to cyclic peptide C5a receptor antagonists of formula (Ia)or formula (Ib), or pharmaceutically acceptable salts thereof,wherein R1a, R1b, R2, R3 and R4 areas defined in the description. C5a receptor antagonists are potentially useful in the treatment of a wide range of 1 disorders,including inflammatory disorders and immune disorders.
(FR) L'invention concerne des dérivés de peptides cycliques, leur utilisation en médecine, des compositions les contenant, leurs procédés de préparation et des intermédiaires utilisés dans de tels procédés. Plus particulièrement, l'invention concerne des peptides cycliques antagonistes des récepteurs C5a de formule (Ia) ou de formule (Ib), ou des sels pharmaceutiquement acceptables de ceux-ci, où R1a, R1b, R2, R3 et R4 sont tels que définis dans la description. Les antagonistes du récepteur C5a sont potentiellement utiles dans le traitement d'une large gamme de troubles 1, y compris les troubles inflammatoires et les troubles immunitaires.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)